Fintel on MSN6h
Piper Sandler Downgrades ESSA Pharma (EPIX)
Fintel reports that on November 4, 2024, Piper Sandler downgraded their outlook for ESSA Pharma (NasdaqCM:EPIX) from ...
Fintel on MSN6h
Oppenheimer Downgrades ESSA Pharma (EPIX)
Fintel reports that on November 4, 2024, Oppenheimer downgraded their outlook for ESSA Pharma (NasdaqCM:EPIX) from Outperform ...
Neurogene Reaches 52-Week High on $200M Private Placement
Neurogene shares reached a 52-week high after the genetic medicine company announced an oversubscribed private placement of about $200 million. The stock was up 44% to $66.55 on Monday, with an ...
Neurogene secures $200M ahead of anticipated study readout
The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett ...
precisionmedicineonline22h
Neurogene Announces $200M PIPE Financing
The company will use the funds to enroll a registrational trial for its investigational gene therapy NGN-401 for Rett Syndrome.